Literature DB >> 10219028

Phacotrabeculectomy versus two-stage operation: a matched study.

F F El-Sayyad1, M H Helal, M M Khalil, M A El-Maghraby.   

Abstract

BACKGROUND AND
OBJECTIVE: To evaluate the efficacy and safety of phacoemulsification and foldable intraocular lens, combined with trabeculectomy (phacotrabeculectomy) in patients with coexisting cataract and glaucoma. PATIENTS AND METHODS: A total of 53 consecutive eyes which underwent phacotrabeculectomy and posterior chamber intraocular lens (PCIOL) were matched and compared with 53 eyes that had trabeculectomy followed by phacoemulsification and posterior chamber intraocular lens (mean interval 3.2 month). The 2 groups were first matched by diagnostic group and subsequently for the closest possible match with other successive variables, including age, gender, race and preoperative glaucoma medications. Mean intraocular pressure (IOP) reduction, visual acuity, antiglaucoma medications, and surgical success as well as complications were compared in both groups.
RESULTS: Mean IOP reduction was 14.5+/-4.1 mmHg in the two-stage group compared to 15.1+/-3.9 in the phacotrabeculectomy group at 6 months follow-up (P<0.1) and 13.8+/-3.9 and 14.6+/-3.7 respectively at 1 year (P<0.1). Visual acuity and complications were comparable.
CONCLUSION: Phacotrabeculectomy provides IOP control statistically comparable to two-stage surgery with earlier visual rehabilitation.

Entities:  

Mesh:

Year:  1999        PMID: 10219028

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers        ISSN: 1082-3069


  3 in total

1.  [Glaucoma and cataract].

Authors:  T H Klink; M Müller; M Zierhut; G Geerling
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

2.  [Comparison of Healon, Healon GV, and Healon 5 in viscotrabeculectomy].

Authors:  M Löw; C Bühler; U Mester
Journal:  Ophthalmologe       Date:  2003-06-25       Impact factor: 1.059

3.  [Combined glaucoma-cataract surgery].

Authors:  F Grehn; T Klink
Journal:  Ophthalmologe       Date:  2004-05-27       Impact factor: 1.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.